老年高危急性冠状动脉综合征患者介入术中应用替罗非班的有效性和安全性Glycoprotein Ⅱb/Ⅲa receptor inhibitors (tirofiban) in percutaneous coronary intervention for elderly high-risk patients with acute coronary syndrome
叶飞,陈绍良,朱中生,张俊杰,林松,周陵,刘玲玲,阚静,段宝祥
摘要(Abstract)：
目的研究老年高危急性冠状动脉综合征(ACS)国人经皮冠状动脉介入术(PCI)中应用替罗非班的有效性和安全性。方法将2004年12月至2006年6月连续的94例老年高危ACS患者随机分为替罗非班治疗组和常规PCI组,前者PCI术前给予替罗非班+半量肝素治疗,后者仅以全量肝素治疗,比较两组PCI术后即刻罪犯血管(CV)的TIMI血流分级,术后6、12h肌酸激酶同工酶(CK-MB)的改变以及术后30d内的主要不良心脏事件(MACE)的发生率、术后出血的发生率和需要输血的比例。结果术后即刻替罗非班组和常规PCI组CV的TIMI血流分级(计帧法)分别为35.6±6.1和38.7±8.2;两组6、12h的CK-MB分别为16.2±3.9mmol/L、13.4±3.9mmol/L和18.4±4.8mmol/L、15.5±5.1mmol/L(P<0.05),而两组间术后30d的MACE发生率以及术后出血、输血的比例差异无统计学意义。结论老年高危ACS患者介入术中使用血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班是安全、有效的,其疗效优于常规治疗。
关键词(KeyWords)： 冠状动脉疾病;替罗非班;血管成形术,经腔,经皮冠状动脉
基金项目(Foundation):
作者(Author): 叶飞,陈绍良,朱中生,张俊杰,林松,周陵,刘玲玲,阚静,段宝祥
参考文献(References)：
- [1]de Feyter PJ,van den Brand M,Jaarman G,et al.Acute coro-nary occlusion during and after percutaneous transluminal coro-nary angioplasty.Circulation,1991,83:927-936.
- [2]Lincoff AM,Popma JJ,Ellis SG,et al.Abrupt vessel closure complicating coronary angioplasty:Clinical,angiographic and therapeutic profile.J Am Coll Cardiol,1992,19:926-935.
- [3]The EPIC investigators.Use of a monoclonal antibody directed a-gainst the platelet glycoproteinⅡb/Ⅲa receptor in high-risk cor-onary angioplasty.N Engl J Med,1994,330:956-961.
- [4]Sekiguchi M,Hoshizaki H,Adachi H,et al.Effects of antiplate-let agents on subacute thrombosis and restenosis after successful coronary stenting:A randomized comparison of ticlopidine and cilostazol.Circ J,2004,68:610-614.
- [5]Blankenship JC.Bleeding complications of glycoproteinⅡb/Ⅲa receptor inhibitors.Am Heart J,1999,138(4Pt2):287-296.
- [6]Elliott MA,Marc C,Peter JLMB,et al.The TIMI Risk Score for Unstable Angina/Non-STElevation MI:A Method for Prognosti-cation and Therapeutic Decision Making.JAMA,2000,284:835-842.
- [7]The platelet receptor inhibition for ischemic syndrome manage-ment in patients limited by unstable signs and symptoms(PRISM-PLUS)trial investigators.Inhibition of the platelet gly-coproteinⅡb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl J Med,1998,38:1488-1497.
- [8]The platelet receptor inhibition for ischemic syndrome manage-ment(PRISM)study investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.N Engl J Med,1998,338:1498-1505.
- [9]ACC/AHA2002guideline update for the management of patients with unstable angina and non-STsegment elevation myocardial in-farction.A report of the American College of Cardiology/Ameri-can Heart Association task force on practice guidelines(commit-tee on the management of patients with unstable angina).J Am Coll Cardiol,2002,40:1366-1374.
- [10]The platelet receptor inhibition for ischemic syndrome manage-ment(PRISM)study investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.N Engl J Med,1998,338:1498-1505.
- [11]The RESTORE investigators.Effects of platelet glycoproteinⅡb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Circulation,1997,96:1445-1453.